Mikael Dolsten, M.D., Ph.D., Appointed to Rocket Pharmaceuticals Board of Directors
Mikael Dolsten, M.D., Ph.D., Appointed to Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company, has announced the appointment of Mikael Dolsten, M.D., Ph.D. to its Board of Directors. This addition emphasizes the company’s commitment to advancing genetic therapies for rare disorders with significant unmet medical needs.
Professional Background of Mikael Dolsten
Dr. Dolsten brings a wealth of experience from his leadership roles at major pharmaceutical companies, making him a pivotal asset in driving innovation within Rocket Pharmaceuticals.
Impact on Rocket Pharmaceuticals
- Enhancing strategic direction in genetic therapies.
- Combining expertise to tackle rare diseases.
- Driving future growth and technological advancements.
For detailed insights, visit the source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.